Home › Companies › HERON THERAPEUTICS INC. › 2023-2024

HERON THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and HERON THERAPEUTICS INC.’s Form 8-K, filed 2024-06-18 (Item 5.07 on EDGAR). Page generated 02 October 2026.

11Ballot items
159Asset managers
1,474Fund votes
2024-06-13Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore HERON THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by HERON THERAPEUTICS INC.

These tallies are HERON THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-18 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

HERON THERAPEUTICS INC. — official shareholder meeting results, meeting held 2024-06-13
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Mr. Collard	87,052,188	622,098	1,794,705	--	29,159,734	Majority: yes
Elect Director: Dr. Dissanaike	86,622,579	875,337	1,971,075	--	29,159,734	Majority: yes
Elect Director: Mr. Johnson	86,610,323	864,346	1,994,322	--	29,159,734	Majority: yes
Elect Director: Mr. Morgan	86,819,401	667,561	1,982,029	--	29,159,734	Majority: yes
Elect Director: Ms. Rodriguez	86,593,635	879,793	1,995,563	--	29,159,734	Majority: yes
Elect Director: Mr. Waage	86,762,924	711,926	1,994,141	--	29,159,734	Majority: yes
Proposal 2: Ratification of the appointment of Withum Smith+Brown, PC as the Company's independent registered public accounting firm for the year ending December 31, 2024:	114,364,367	358,527	3,905,831	--	0	Majority: yes
Proposal 3: Nonbinding advisory vote to approve compensation paid to the Company's Named Executive Officers during the year ended December 31, 2023:	72,711,988	14,427,205	2,329,798	--	29,159,734	Majority: yes
Proposal 4: Amendment to the Company's Certificate of Incorporation, as amended, to increase the aggregate number of authorized shares of the Company's common stock by 175,000,000 from 225,000,000 to 400,000,000:	104,392,527	11,372,028	2,864,170	--	0	Majority: yes
Proposal 5: Amendment to the Company's 2007 Amended and Restated Equity Incentive Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder by 7,500,000 from 39,190,000 to 46,690,000:	62,949,448	24,467,411	2,052,132	--	29,159,734	Majority: yes
Proposal 6: Amendment to the Company's 1997 Employee Stock Purchase Plan, as amended, to increase the number of shares of the Company's common stock authorized for issuance thereunder by 1,200,000 from 2,225,000 to 3,425,000:	82,707,274	5,000,632	1,761,085	--	29,159,734	Majority: yes

Source: HERON THERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-06-18 — read the filing on EDGAR.

How asset managers voted at the HERON THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 159 asset managers that disclosed a HERON THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. TO APPROVE, ON A NONBINDING ADVISORY BASIS, COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS DURING THE FISCAL YEAR ENDED DECEMBER 31, 2023.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%AGAINST 17%

FOR: 72,711,988AGAINST: 14,427,205

HERON THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Nonbinding advisory vote to approve compensation paid to the Company's Named Executive Officers during the year ended December 31, 2023:”): 72,711,988 for, 14,427,205 against, per its Form 8-K filed 2024-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 150,653,158 outstanding shares: 48.3% for, 10% against (58% of the company cast a for/against vote).

The 158 asset managers below cast 84% of the shares they voted on this item FOR (63,528,984 for, 12,068,090 against).

FOR 78%AGAINST 15%

FOR: 63,528,984 (77.8%)AGAINST: 12,068,090 (14.8%)ABSTAIN: 3,735,982 (4.6%)UNKNOWN: 2,292,418 (2.8%)

Largest asset managers voting on “TO APPROVE, ON A NONBINDING ADVISORY BASIS, COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS DURING THE FISCA” at HERON THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Rubric Capital Management LP	26,713,503	0	0	For
ORBIMED ADVISORS LLC	0	8,268,036	0	Against
Velan Capital Investment Management LP	6,986,744	0	0	For
Vanguard	5,399,401	0	0	For
BlackRock	5,234,465	0	0	For
FRANKLIN ADVISERS INC	4,902,703	0	0	For
State Street	2,317,773	0	0	For
PALISADE CAPITAL MANAGEMENT, LP	2,292,694	0	0	For
JW Asset Management, LLC	0	0	0	Unknown
Orchard Capital Management, LLC	0	0	2,018,126	Abstain
Clearline Capital LP	1,747,533	0	0	For
Monaco Asset Management SAM	0	0	1,683,164	Abstain
FRANKLIN STRATEGIC SERIES	1,632,692	0	0	For
NEW YORK STATE COMMON RETIREMENT FUND	0	1,094,219	0	Against
Charles Schwab	0	1,005,880	0	Against
ADAGE CAPITAL PARTNERS GP, L.L.C.	936,418	0	0	For
Northern Trust	506,537	126	0	For
SEI	0	482,322	0	Against
DE Shaw	420,954	0	0	For
Renaissance	410,346	0	0	For
MELLON INVESTMENTS Corp	388,983	0	0	For
Wellington	0	374,702	0	Against
Equitable	274,608	0	0	For
Goldman Sachs	254,623	0	0	For
HIGHLAND GLOBAL ALLOCATION FUND	0	232,800	0	Against

Showing the 25 largest of 158 asset managers. See all 158 in the interactive database.

2. TO AMEND THE ESPP TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER BY 1,200,000 FROM 2,225,000 TO 3,425,000.

COMPENSATIONMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 82,707,274AGAINST: 5,000,632

HERON THERAPEUTICS INC.’s own tally for this item (“Proposal 6: Amendment to the Company's 1997 Employee Stock Purchase Plan, as amended, to increase the number of shares of the Company's common stock authorized for issuance thereunder by 1,200,000 from 2,225,000 to 3,425”): 82,707,274 for, 5,000,632 against, per its Form 8-K filed 2024-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 150,653,158 outstanding shares: 54.9% for, 3% against (58% of the company cast a for/against vote).

The 42 asset managers below cast 99.2% of the shares they voted on this item FOR (12,588,876 for, 96,352 against).

FOR 99.2%

FOR: 12,588,876 (99.2%)AGAINST: 96,352 (0.8%)

Largest asset managers voting on “TO AMEND THE ESPP TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER BY 1,200” at HERON THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	5,357,334	0	For
BlackRock	2,600,053	0	For
FRANKLIN STRATEGIC SERIES	1,632,692	0	For
State Street	582,775	0	For
Charles Schwab	502,940	0	For
Equitable	274,608	0	For
SEI	240,911	0	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	0	For
Jacob Funds Inc.	162,448	61,660	For
QUANTITATIVE MASTER SERIES LLC	185,313	0	For
Lincoln Financial	134,700	0	For
TIAA	116,628	0	For
Fidelity	93,989	0	For
Brighthouse	19,319	34,692	Against
Federated Hermes	47,993	0	For
Northern Trust	46,803	0	For
Zacks Trust	41,348	0	For
GRIMES & COMPANY, INC.	40,162	0	For
Pacific Life	33,105	0	For
Voya	32,333	0	For
Bridge Builder Trust	24,518	0	For
Legg Mason	21,926	0	For
John Hancock	19,729	0	For
AQR	19,191	0	For
Victory Capital	18,762	0	For

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

3. To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Adam Morgan

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%

FOR: 86,819,401AGAINST: 667,561

HERON THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mr. Morgan”): 86,819,401 for, 667,561 against, per its Form 8-K filed 2024-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 150,653,158 outstanding shares: 58% for, 0.5% against (58% of the company cast a for/against vote).

The 41 asset managers below cast 100% of the shares they voted on this item FOR (12,610,374 for, 0 against).

FOR 99.7%

FOR: 12,610,374 (99.7%)ABSTAIN: 34,692 (0.3%)

Largest asset managers voting on “To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successo” at HERON THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	5,357,334	0	For
BlackRock	2,600,053	0	For
FRANKLIN STRATEGIC SERIES	1,632,692	0	For
State Street	582,775	0	For
Charles Schwab	502,940	0	For
Equitable	274,608	0	For
SEI	240,911	0	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	0	For
Jacob Funds Inc.	224,108	0	For
QUANTITATIVE MASTER SERIES LLC	185,313	0	For
Lincoln Financial	134,700	0	For
TIAA	116,628	0	For
Fidelity	93,989	0	For
Brighthouse	19,319	34,692	Abstain
Federated Hermes	47,993	0	For
Northern Trust	46,803	0	For
Zacks Trust	41,348	0	For
Pacific Life	33,105	0	For
Voya	32,333	0	For
Bridge Builder Trust	24,518	0	For
Legg Mason	21,926	0	For
John Hancock	19,729	0	For
AQR	19,191	0	For
Victory Capital	18,762	0	For
Principal Exchange-Traded Funds	16,236	0	For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

4. To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Christian Waage

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%

FOR: 86,762,924AGAINST: 711,926

HERON THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mr. Waage”): 86,762,924 for, 711,926 against, per its Form 8-K filed 2024-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 150,653,158 outstanding shares: 58% for, 0.5% against (58% of the company cast a for/against vote).

The 41 asset managers below cast 99.9% of the shares they voted on this item FOR (12,603,246 for, 7,128 against).

FOR 99.6%

FOR: 12,603,246 (99.7%)AGAINST: 7,128 (0.1%)ABSTAIN: 34,692 (0.3%)

Largest asset managers voting on “To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successo” at HERON THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	5,357,334	0	For
BlackRock	2,600,053	0	For
FRANKLIN STRATEGIC SERIES	1,632,692	0	For
State Street	582,775	0	For
Charles Schwab	502,940	0	For
Equitable	274,608	0	For
SEI	240,911	0	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	0	For
Jacob Funds Inc.	224,108	0	For
QUANTITATIVE MASTER SERIES LLC	185,313	0	For
Lincoln Financial	134,700	0	For
TIAA	116,628	0	For
Fidelity	93,989	0	For
Brighthouse	19,319	34,692	Abstain
Federated Hermes	47,993	0	For
Northern Trust	46,803	0	For
Zacks Trust	41,348	0	For
Pacific Life	33,105	0	For
Voya	32,333	0	For
Bridge Builder Trust	24,518	0	For
Legg Mason	21,926	0	For
John Hancock	19,729	0	For
AQR	19,191	0	For
Victory Capital	18,762	0	For
Principal Exchange-Traded Funds	16,236	0	For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

5. To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Craig Collard

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%

FOR: 87,052,188AGAINST: 622,098

HERON THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mr. Collard”): 87,052,188 for, 622,098 against, per its Form 8-K filed 2024-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 150,653,158 outstanding shares: 58% for, 0.5% against (58% of the company cast a for/against vote).

The 41 asset managers below cast 100% of the shares they voted on this item FOR (12,610,374 for, 0 against).

FOR 99.7%

FOR: 12,610,374 (99.7%)ABSTAIN: 34,692 (0.3%)

Largest asset managers voting on “To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successo” at HERON THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	5,357,334	0	For
BlackRock	2,600,053	0	For
FRANKLIN STRATEGIC SERIES	1,632,692	0	For
State Street	582,775	0	For
Charles Schwab	502,940	0	For
Equitable	274,608	0	For
SEI	240,911	0	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	0	For
Jacob Funds Inc.	224,108	0	For
QUANTITATIVE MASTER SERIES LLC	185,313	0	For
Lincoln Financial	134,700	0	For
TIAA	116,628	0	For
Fidelity	93,989	0	For
Brighthouse	19,319	34,692	Abstain
Federated Hermes	47,993	0	For
Northern Trust	46,803	0	For
Zacks Trust	41,348	0	For
Pacific Life	33,105	0	For
Voya	32,333	0	For
Bridge Builder Trust	24,518	0	For
Legg Mason	21,926	0	For
John Hancock	19,729	0	For
AQR	19,191	0	For
Victory Capital	18,762	0	For
Principal Exchange-Traded Funds	16,236	0	For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

6. To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Craig Johnson

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.0% Majority: yes · of votes cast

FOR 99.0%

FOR: 86,610,323AGAINST: 864,346

HERON THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mr. Johnson”): 86,610,323 for, 864,346 against, per its Form 8-K filed 2024-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 150,653,158 outstanding shares: 57% for, 0.6% against (58% of the company cast a for/against vote).

The 41 asset managers below cast 99.6% of the shares they voted on this item FOR (12,561,961 for, 48,413 against).

FOR 99.3%

FOR: 12,561,961 (99.3%)AGAINST: 48,413 (0.4%)ABSTAIN: 34,692 (0.3%)

Largest asset managers voting on “To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successo” at HERON THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	5,357,334	0	0	For
BlackRock	2,600,053	0	0	For
FRANKLIN STRATEGIC SERIES	1,632,692	0	0	For
State Street	582,775	0	0	For
Charles Schwab	502,940	0	0	For
Equitable	274,608	0	0	For
SEI	240,911	0	0	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	0	0	For
Jacob Funds Inc.	224,108	0	0	For
QUANTITATIVE MASTER SERIES LLC	185,313	0	0	For
Lincoln Financial	134,700	0	0	For
TIAA	116,628	0	0	For
Fidelity	93,989	0	0	For
Brighthouse	19,319	0	34,692	Abstain
Federated Hermes	0	47,993	0	Against
Northern Trust	46,803	0	0	For
Zacks Trust	41,348	0	0	For
Pacific Life	33,105	0	0	For
Voya	32,333	0	0	For
Bridge Builder Trust	24,518	0	0	For
Legg Mason	21,926	0	0	For
John Hancock	19,729	0	0	For
AQR	19,191	0	0	For
Victory Capital	18,762	0	0	For
Principal Exchange-Traded Funds	16,236	0	0	For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

7. To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Sharmila Dissanaike, M.D., FACS, FCCM

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 86,622,579AGAINST: 875,337

HERON THERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Dissanaike”): 86,622,579 for, 875,337 against, per its Form 8-K filed 2024-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 150,653,158 outstanding shares: 57% for, 0.6% against (58% of the company cast a for/against vote).

The 41 asset managers below cast 99.6% of the shares they voted on this item FOR (12,561,961 for, 48,413 against).

FOR 99.3%

FOR: 12,561,961 (99.3%)AGAINST: 48,413 (0.4%)ABSTAIN: 34,692 (0.3%)

Largest asset managers voting on “To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successo” at HERON THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	5,357,334	0	0	For
BlackRock	2,600,053	0	0	For
FRANKLIN STRATEGIC SERIES	1,632,692	0	0	For
State Street	582,775	0	0	For
Charles Schwab	502,940	0	0	For
Equitable	274,608	0	0	For
SEI	240,911	0	0	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	0	0	For
Jacob Funds Inc.	224,108	0	0	For
QUANTITATIVE MASTER SERIES LLC	185,313	0	0	For
Lincoln Financial	134,700	0	0	For
TIAA	116,628	0	0	For
Fidelity	93,989	0	0	For
Brighthouse	19,319	0	34,692	Abstain
Federated Hermes	0	47,993	0	Against
Northern Trust	46,803	0	0	For
Zacks Trust	41,348	0	0	For
Pacific Life	33,105	0	0	For
Voya	32,333	0	0	For
Bridge Builder Trust	24,518	0	0	For
Legg Mason	21,926	0	0	For
John Hancock	19,729	0	0	For
AQR	19,191	0	0	For
Victory Capital	18,762	0	0	For
Principal Exchange-Traded Funds	16,236	0	0	For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

8. To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Susan Rodriguez

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 86,593,635AGAINST: 879,793

HERON THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ms. Rodriguez”): 86,593,635 for, 879,793 against, per its Form 8-K filed 2024-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 150,653,158 outstanding shares: 57% for, 0.6% against (58% of the company cast a for/against vote).

The 41 asset managers below cast 99.6% of the shares they voted on this item FOR (12,561,961 for, 48,413 against).

FOR 99.3%

FOR: 12,561,961 (99.3%)AGAINST: 48,413 (0.4%)ABSTAIN: 34,692 (0.3%)

Largest asset managers voting on “To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successo” at HERON THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	5,357,334	0	0	For
BlackRock	2,600,053	0	0	For
FRANKLIN STRATEGIC SERIES	1,632,692	0	0	For
State Street	582,775	0	0	For
Charles Schwab	502,940	0	0	For
Equitable	274,608	0	0	For
SEI	240,911	0	0	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	0	0	For
Jacob Funds Inc.	224,108	0	0	For
QUANTITATIVE MASTER SERIES LLC	185,313	0	0	For
Lincoln Financial	134,700	0	0	For
TIAA	116,628	0	0	For
Fidelity	93,989	0	0	For
Brighthouse	19,319	0	34,692	Abstain
Federated Hermes	0	47,993	0	Against
Northern Trust	46,803	0	0	For
Zacks Trust	41,348	0	0	For
Pacific Life	33,105	0	0	For
Voya	32,333	0	0	For
Bridge Builder Trust	24,518	0	0	For
Legg Mason	21,926	0	0	For
John Hancock	19,729	0	0	For
AQR	19,191	0	0	For
Victory Capital	18,762	0	0	For
Principal Exchange-Traded Funds	16,236	0	0	For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

9. TO AMEND THE 2007 PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER BY 7,500,000 FROM 39,190,000 TO 46,690,000.

COMPENSATIONMajority of the votes cast: yes

72% Majority: yes · of votes cast

FOR 72%AGAINST 28%

FOR: 62,949,448AGAINST: 24,467,411

HERON THERAPEUTICS INC.’s own tally for this item (“Proposal 5: Amendment to the Company's 2007 Amended and Restated Equity Incentive Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder by 7,500,000 from 39,190,000 to 46,”): 62,949,448 for, 24,467,411 against, per its Form 8-K filed 2024-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 150,653,158 outstanding shares: 42% for, 16% against (58% of the company cast a for/against vote).

The 41 asset managers below cast 87% of the shares they voted on this item FOR (10,944,463 for, 1,665,911 against).

FOR 87%13%

FOR: 10,944,463 (86.6%)AGAINST: 1,665,911 (13.2%)ABSTAIN: 34,692 (0.3%)

Largest asset managers voting on “TO AMEND THE 2007 PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER BY ” at HERON THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	5,357,334	0	0	For
BlackRock	2,600,053	0	0	For
FRANKLIN STRATEGIC SERIES	1,632,692	0	0	For
State Street	0	582,775	0	Against
Charles Schwab	502,940	0	0	For
Equitable	109,578	165,030	0	Against
SEI	240,911	0	0	For
HIGHLAND GLOBAL ALLOCATION FUND	0	232,800	0	Against
Jacob Funds Inc.	162,448	61,660	0	For
QUANTITATIVE MASTER SERIES LLC	185,313	0	0	For
Lincoln Financial	0	134,700	0	Against
TIAA	0	116,628	0	Against
Fidelity	0	93,989	0	Against
Brighthouse	0	19,319	34,692	Abstain
Federated Hermes	47,993	0	0	For
Northern Trust	0	46,803	0	Against
Zacks Trust	41,348	0	0	For
Pacific Life	33,105	0	0	For
Voya	0	32,333	0	Against
Bridge Builder Trust	24,518	0	0	For
Legg Mason	0	21,926	0	Against
John Hancock	0	19,729	0	Against
AQR	0	19,191	0	Against
Victory Capital	0	18,762	0	Against
Principal Exchange-Traded Funds	0	16,236	0	Against

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

10. TO AMEND THE COMPANY'S CERTIFICATE OF INCORPORATION TO INCREASE THE AGGREGATE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK BY 175,000,000 FROM 225,000,000 TO 400,000,000.

CAPITAL STRUCTUREMajority of the votes cast: yes

90% Majority: yes · of votes cast

FOR 90%10%

FOR: 104,392,527AGAINST: 11,372,028

HERON THERAPEUTICS INC.’s own tally for this item (“Proposal 4: Amendment to the Company's Certificate of Incorporation, as amended, to increase the aggregate number of authorized shares of the Company's common stock by 175,000,000 from 225,000,000 to 400,000,000:”): 104,392,527 for, 11,372,028 against, per its Form 8-K filed 2024-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 150,653,158 outstanding shares: 69% for, 8% against (77% of the company cast a for/against vote).

The 41 asset managers below cast 99.2% of the shares they voted on this item FOR (12,548,714 for, 96,352 against).

FOR 99.2%

FOR: 12,548,714 (99.2%)AGAINST: 96,352 (0.8%)

Largest asset managers voting on “TO AMEND THE COMPANY'S CERTIFICATE OF INCORPORATION TO INCREASE THE AGGREGATE NUMBER OF AUTHORIZED SHARES OF C” at HERON THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	5,357,334	0	For
BlackRock	2,600,053	0	For
FRANKLIN STRATEGIC SERIES	1,632,692	0	For
State Street	582,775	0	For
Charles Schwab	502,940	0	For
Equitable	274,608	0	For
SEI	240,911	0	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	0	For
Jacob Funds Inc.	162,448	61,660	For
QUANTITATIVE MASTER SERIES LLC	185,313	0	For
Lincoln Financial	134,700	0	For
TIAA	116,628	0	For
Fidelity	93,989	0	For
Brighthouse	19,319	34,692	Against
Federated Hermes	47,993	0	For
Northern Trust	46,803	0	For
Zacks Trust	41,348	0	For
Pacific Life	33,105	0	For
Voya	32,333	0	For
Bridge Builder Trust	24,518	0	For
Legg Mason	21,926	0	For
John Hancock	19,729	0	For
AQR	19,191	0	For
Victory Capital	18,762	0	For
Principal Exchange-Traded Funds	16,236	0	For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

11. TO RATIFY THE APPOINTMENT OF WITHUM AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.

AUDIT-RELATEDMajority of the votes cast: yes

99.6% Majority: yes · of votes cast

FOR 99.6%

FOR: 114,364,367AGAINST: 358,527

HERON THERAPEUTICS INC.’s own tally for this item (“Proposal 2: Ratification of the appointment of Withum Smith+Brown, PC as the Company's independent registered public accounting firm for the year ending December 31, 2024:”): 114,364,367 for, 358,527 against, per its Form 8-K filed 2024-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 150,653,158 outstanding shares: 76% for, 0.3% against (76% of the company cast a for/against vote).

The 41 asset managers below cast 100% of the shares they voted on this item FOR (12,610,374 for, 0 against).

FOR 99.7%

FOR: 12,610,374 (99.7%)ABSTAIN: 34,692 (0.3%)

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF WITHUM AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR E” at HERON THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	5,357,334	0	For
BlackRock	2,600,053	0	For
FRANKLIN STRATEGIC SERIES	1,632,692	0	For
State Street	582,775	0	For
Charles Schwab	502,940	0	For
Equitable	274,608	0	For
SEI	240,911	0	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	0	For
Jacob Funds Inc.	224,108	0	For
QUANTITATIVE MASTER SERIES LLC	185,313	0	For
Lincoln Financial	134,700	0	For
TIAA	116,628	0	For
Fidelity	93,989	0	For
Brighthouse	19,319	34,692	Abstain
Federated Hermes	47,993	0	For
Northern Trust	46,803	0	For
Zacks Trust	41,348	0	For
Pacific Life	33,105	0	For
Voya	32,333	0	For
Bridge Builder Trust	24,518	0	For
Legg Mason	21,926	0	For
John Hancock	19,729	0	For
AQR	19,191	0	For
Victory Capital	18,762	0	For
Principal Exchange-Traded Funds	16,236	0	For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

Largest HERON THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked by the number of HERON THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 150,653,158 shares outstanding at the time of that meeting.

Top HERON THERAPEUTICS INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	Rubric Capital Management LP	17.73%
2	ORBIMED ADVISORS LLC	5.49%
3	Velan Capital Investment Management LP	4.64%
4	Vanguard	3.58%
5	BlackRock	3.47%
6	FRANKLIN ADVISERS INC	3.25%
7	State Street	1.54%
8	PALISADE CAPITAL MANAGEMENT, LP	1.52%
9	JW Asset Management, LLC	1.52%
10	Orchard Capital Management, LLC	1.34%

Reported HERON THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

HERON THERAPEUTICS INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Rubric Capital Management LP	17.73%	DEF14A
BlackRock	6.63%	13F
Vanguard Group	5.62%	13F
Adam Morgan	4.70%	DEF14A
Franklin Templeton	4.23%	13F
Geode Capital	1.86%	13F
D.E. Shaw	1.79%	13F
State Street	1.62%	13F
Renaissance Technologies	1.60%	13F
Goldman Sachs	0.88%	13F

Percentages above are of 150,653,158 shares outstanding, as reported by HERON THERAPEUTICS INC. on its Form 10-Q dated 2024-05-02 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from HERON THERAPEUTICS INC.’s 10-Q dated 2024-05-02. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At HERON THERAPEUTICS INC.'s shareholder meeting held 2024-06-13, in the 2023-2024 proxy season, 159 asset managers reported how they voted on 11 ballot items in their SEC Form N-PX filings, covering 1,474 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NONBINDING ADVISORY BASIS, COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS… — FOR was 83% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: HERON THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-18.

HERON THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.